MGX · Metagenomi Therapeutics, Inc.
$1.24
+0.00 (+0.00%)
At close · Jul 17
Market Cap
$46.68M
Shares
37,646,858
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$25.21M
-51.8%
FY2025
Net Income
-$87.87M
-12.6%
FY2025
Operating Margin
-380.85%
-210.8pp
FY2025
Diluted EPS
-$2.36
0%
FY2025
Operating Cash Flow
-$88.89M
+18.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 |
|---|---|---|---|
| $22.33M | $25.21M | $52.3M | |
| $88.59M | $94.43M | $109.18M | |
| $26.52M | $26.79M | $32.02M | |
| $115.11M | $121.22M | $141.2M | |
| -$92.78M | -$96.01M | -$88.9M | |
| — | -380.85% | -170% | |
| $8.12M | $9.47M | $14.72M | |
| $6.75M | $8.09M | $5.33M | |
| -$86.03M | -$87.93M | -$83.57M | |
| -$146K | -$58K | -$5.51M | |
| -$85.89M | -$87.87M | -$78.06M | |
| — | -348.54% | -149.26% | |
| -$86.55M | -$88.32M | -$77.25M | |
| USD/shares | — | -$2.36 | -$2.36 |
| USD/shares | — | -$2.36 | -$2.36 |
| shares | — | 37.25M | 33.03M |
| shares | — | 37.25M | 33.03M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.75×
EV/EBIT
—
Biotechnology median 26.36×
P/E (TTM)
—
Biotechnology median 7.37×